BUZZ-制药商 Incyte 下调年度营收预期后股价下跌

路透中文

Feb 10

BUZZ-制药商 Incyte 下调年度营收预期后股价下跌

2月10日 - ** 制药商IncyteINCY.O股价盘前下跌5%至103.62美元，因2026年收入预期疲软 (link)

** 预测2026年收入在47.7亿至49.4亿美元之间，低于55.2亿美元的预期--LSEG汇编的数据

** 公司表示主要增长动力Opzelura将表现不佳，引发了对抵消顶级畅销产品Jakafi即将到来的专利损失能力的担忧

** INCY 公布第四季度调整后每股收益为1.80美元，分析师平均预期为1.93美元--LSEG汇编的数据

** 公司第四季度产品支出增长快于产品收入增长

** INCY 的研发费用同比增长 37%

** 公司利润四个季度以来首次低于预期 - LSEG数据

** 然而，由于血液病药物 Jakafi的需求强劲，第四季度收入超出分析师预期

** 2025 年 INCY 股价上涨 43%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610239016"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610239016\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610239016?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-02-10 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610239016","market":"us","top_or_hot":-1,"title":"BUZZ-制药商 Incyte 下调年度营收预期后股价下跌","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-制药商 Incyte 下调年度营收预期后股价下跌</title></head><body><p>\n<span>2月10日</span><span> - </span>** 制药商Incyte<span>INCY.O</span>股价盘前下跌5%至103.62美元，因2026年收入预期疲软 (<span>link</span>) </p><p>** 预测2026年收入在47.7亿至49.4亿美元之间，低于55.2亿美元的预期<span>--LSEG汇编的数据</span></p><p>** 公司表示主要增长动力Opzelura将表现不佳，引发了对抵消顶级畅销产品Jakafi即将到来的专利损失能力的担忧</p><p>** INCY 公布第四季度调整后每股收益为1.80美元，分析师平均预期为1.93美元--LSEG汇编的数据 </p><p>** 公司第四季度产品支出增长快于产品收入增长</p><p>** INCY 的研发费用同比增长 37%</p><p>** 公司利润四个季度以来首次低于预期 - LSEG数据</p><p>** 然而，由于<span>血液病药物 </span>Jakafi的需求强劲，第四季度收入超出分析师预期</p><p>** 2025 年 INCY 股价上涨 43%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-制药商 Incyte 下调年度营收预期后股价下跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-制药商 Incyte 下调年度营收预期后股价下跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-02-10 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-制药商 Incyte 下调年度营收预期后股价下跌</title></head><body><p>\n<span>2月10日</span><span> - </span>** 制药商Incyte<span>INCY.O</span>股价盘前下跌5%至103.62美元，因2026年收入预期疲软 (<span>link</span>) </p><p>** 预测2026年收入在47.7亿至49.4亿美元之间，低于55.2亿美元的预期<span>--LSEG汇编的数据</span></p><p>** 公司表示主要增长动力Opzelura将表现不佳，引发了对抵消顶级畅销产品Jakafi即将到来的专利损失能力的担忧</p><p>** INCY 公布第四季度调整后每股收益为1.80美元，分析师平均预期为1.93美元--LSEG汇编的数据 </p><p>** 公司第四季度产品支出增长快于产品收入增长</p><p>** INCY 的研发费用同比增长 37%</p><p>** 公司利润四个季度以来首次低于预期 - LSEG数据</p><p>** 然而，由于<span>血液病药物 </span>Jakafi的需求强劲，第四季度收入超出分析师预期</p><p>** 2025 年 INCY 股价上涨 43%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL4T3Z61IP:1","article_id":"2610239016","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610239016","pubTimestamp":1770730297,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","INCY":"因塞特医疗","BK4588":"碎股","BK4550":"红杉资本持仓"},"translate_title":"BUZZ-Drug maker Incyte falls after cutting annual revenue forecast","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"BUZZ-制药商 Incyte 下调年度营收预期后股价下跌\n2月10日 - ** 制药商IncyteINCY.O股价盘前下跌5%至103.62美元，因2026年收入预期疲软 (link) ** 预测2026年收入在47.7亿至49.4亿美元之间，低于55.2亿美元的预期--LSEG汇编的数据** 公司表示主要增长动力Opzelura将表现不佳，引发了对抵消顶级畅销产品Jakafi即将到来的专利损失能力的担忧** INCY 公布第四季度调整后每股收益为1.80美元，分析师平均预期为1.93美元--LSEG汇编的数据 ** 公司第四季度产品支出增长快于产品收入增长** INCY 的研发费用同比增长 37%** 公司利润四个季度以来首次低于预期 - LSEG数据** 然而，由于血液病药物 Jakafi的需求强劲，第四季度收入超出分析师预期** 2025 年 INCY 股价上涨 43%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}